{"nctId":"NCT01010633","briefTitle":"Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery","startDateStruct":{"date":"2009-11"},"conditions":["Inflammation","Pain"],"count":406,"armGroups":[{"label":"Loteprednol Etabonate","type":"EXPERIMENTAL","interventionNames":["Drug: Loteprednol Etabonate"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle of Loteprednol Etabonate"]}],"interventions":[{"name":"Vehicle of Loteprednol Etabonate","otherNames":[]},{"name":"Loteprednol Etabonate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who are at least 18 years of age.\n* Subjects who are candidates for routine, uncomplicated cataract surgery.\n* Subjects who, in the Investigator's opinion, have potential postoperative pinholed Snellen visual acuity (VA) of at least 20/200 in the study eye.\n\nExclusion Criteria:\n\n* Subjects who have known hypersensitivity or contraindication to the study drug or components.\n* Subjects with a severe/serious ocular condition, or any other unstable medical condition, that in the investigator's opinion may preclude study treatment or follow-up.\n* Subjects with elevated intraocular pressure (\\>/= 21mm Hg), uncontrolled glaucoma, or being treated for glaucoma in the study eye.\n* Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the non-study eye.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Resolution of Anterior Chamber Cells (ACC).","description":"Number of Study eyes with complete resolution(Grade 0) of anterior chamber cells (ACC) for loteprednol and vehicle. Accumulation of white cells in aqueous graded on a scale of 0-4 where grade 0=no cells. Investigators assessed ACC using a slit lamp.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Resolution of Anterior Chamber Cells.","description":"Study eyes with complete resolution of anterior chamber cells (ACC)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]},{"type":"PRIMARY","title":"Grade 0 Pain","description":"Number of eyes with grade 0 ocular pain. Ocular pain, defined as a positive sensation of the eye, based on a 0-5 scale where grade 0 equaled no pain and grade 5 equaled severe pain. Ocular pain graded by participants.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":203},"commonTop":[]}}}